Carbamate analogues of amsacrine active against non-cycling cells: relative activity against topoisomerases IIalpha and beta.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Cancer Chemotherapy and Pharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Chemistry

• Identifiers
  PMID 10447574
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patterns of cross-resistance in a multidrug-resistant small-cell lung carcinoma cell line

  2008cited by this paper
• Novel carbamate analogues of amsacrine with activity against non-cycling murine and human tumour cells

  2004cited by this paper
• Using yeast to study resistance to topoisomerase II-targeting drugs

  2004cited by this paper
• In vitro assessment ofN-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance

  2004cited by this paper
• Eukaryotic DNA topoisomerase II beta.

  1998cited by this paper
• Complementation of temperature-sensitive topoisomerase II mutations in Saccharomyces cerevisiae by a human TOP2β construct allows the study of topoisomerase IIβ inhibitors in yeast.

  1997cited by this paper
• A carbamate analogue of amsacrine with activity against non-cycling cells stimulates topoisomerase II cleavage at DNA sites distinct from those of amsacrine.

  1997cited by this paper
• Role of topoisomerase II beta in the resistance of 9-OH-ellipticine-resistant Chinese hamster fibroblasts to topoisomerase II inhibitors.

  1997cited by this paper
• The potential of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide]to circumvent three multidrug-resistance phenotypes in vitro

  1997cited by this paper
• DNA topoisomerases.

  1996cited by this paper
• From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives.

  1996cited by this paper
• Cytoplasmic localization of a mutant M(r) 160,000 topoisomerase II alpha is associated with the loss of putative bipartite nuclear localization signals in a drug-resistant human lung cancer cell line.

  1995cited by this paper
• Expression, Domain Structure, and Enzymatic Properties of an Active Recombinant Human DNA Topoisomerase IIβ (*)

  1995cited by this paper
• Characterization of an altered DNA topoisomerase ii-alpha from a mitoxantrone resistant Mammalian-cell line hypersensitive to DNA cross-linking agents.

  1995cited by this paper
• Alterations in the topoisomerase II alpha gene, messenger RNA, and subcellular protein distribution as well as reduced expression of the DNA topoisomerase II beta enzyme in a mitoxantrone-resistant HL-60 human leukemia cell line.

  1995cited by this paper
• Altered subcellular distribution of topoisomerase II alpha in a drug-resistant human small cell lung cancer cell line.

  1994cited by this paper
• Disruption of a topoisomerase-DNA cleavage complex by a DNA helicase.

  1994cited by this paper
• Topoisomerase II activity involved in cleaving DNA into topological domains is altered in a multiple drug-resistant Chinese hamster ovary cell line.

  1993cited by this paper
• Use of yeast in the study of anticancer drugs targeting DNA topoisomerases: expression of a functional recombinant human DNA topoisomerase II alpha in yeast.

  1993cited by this paper
• Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line.

  1993cited by this paper
• Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line.

  1991cited by this paper
• Multiple patterns of resistance of human leukemia cell sublines to amsacrine analogues.

  1990cited by this paper
• Selectivity of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide towards Lewis lung carcinoma and human tumour cell lines in vitro.

  1989cited by this paper
• Topoisomerase-targeting antitumor drugs.

  1989cited by this paper
• Cell line selectivity and DNA breakage properties of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide: role of DNA topoisomerase II.

  1988cited by this paper
• DNA topoisomerase-targeting antitumor drugs can be studied in yeast.

  1988cited by this paper
• Potential antitumor agents. 50. In vivo solid-tumor activity of derivatives of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.

  1987cited by this paper
• Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity.

  1986cited by this paper
• Eukaryotic topoisomerase II. Characterization of enzyme turnover.

  1986cited by this paper
• m-AMSA: a review of clinical data.

  1985cited by this paper
• Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.

  1984cited by this paper
• Potential antitumor agents. 36. Quantitative relationships between experimental antitumor activity, toxicity, and structure for the general class of 9-anilinoacridine antitumor agents.

  1982cited by this paper
• The experimental antitumour properties of three congeners of the acridylmethanesulphonanilide (AMSA) series.

  1974cited by this paper
• Potential antitumor agents. 12. 9-Anilinoacridines.

  1972cited by this paper

• Smoothed Potential MD Simulations for Dissociation Kinetics of Etoposide To Unravel Isoform Specificity in Targeting Human Topoisomerase II

  2019cites this paper
• Acridine and its derivatives: a patent review (2009 – 2013)

  2014cites this paper
• A high-throughput fluorescence anisotropy-based assay for human topoisomerase II β-catalyzed ATP-dependent supercoiled DNA relaxation.

  2014cites this paper
• Niche for acridine derivatives in anticancer therapy.

  2013cites this paper
• Novel Strategies for Overcoming Multidrug Resistance in Cancer

  2012cites this paper
• Differential Selection of Acridine Resistance Mutations in Human DNA Topoisomerase IIβ Is Dependent on the Acridine Structure

  2007cites this paper
• Mutation E522K in human DNA topoisomerase IIbeta confers resistance to methyl N-(4'-(9-acridinylamino)-phenyl)carbamate hydrochloride and methyl N-(4'-(9-acridinylamino)-3-methoxy-phenyl) methane sulfonamide but hypersensitivity to etoposide.

  2004cites this paper
• Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000.

  2003cites this paper
• Sequence-specific interactions of drugs interfering with the topoisomerase-DNA cleavage complex.

  2002cites this paper
• Acridine derivatives as chemotherapeutic agents.

  2002cites this paper
• Interest of acridine derivatives in the anticancer chemotherapy.

  2001cites this paper
• An investigation into the formation of N- [2-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) and 6-[2-(dimethylamino)ethylamino]- 3-hydroxy-7H-indeno[2, 1-C]quinolin-7-one dihydrochloride (TAS-103) stabilised DNA topoisomerase I and II cleavable complexes in human leukaemia cells.

  2000cites this paper
• Establishment and Characterization of 6‐[[2‐(Dimethylamino)ethyl]amino]‐3‐hydroxy‐7H‐indeno[2,1‐c]quinolin‐7‐one dihydrochloride (TAS‐103)‐resistant Cell Lines

  2000cites this paper
• [The DACA].

  1999cites this paper